Leslie Shaw to Clinical Trials as Topic
This is a "connection" page, showing publications Leslie Shaw has written about Clinical Trials as Topic.
Connection Strength
0.426
-
Weiner MW, Kanoria S, Miller MJ, Aisen PS, Beckett LA, Conti C, Diaz A, Flenniken D, Green RC, Harvey DJ, Jack CR, Jagust W, Lee EB, Morris JC, Nho K, Nosheny R, Okonkwo OC, Perrin RJ, Petersen RC, Rivera-Mindt M, Saykin AJ, Shaw LM, Toga AW, Tosun D, Veitch DP. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. Alzheimers Dement. 2025 Jan; 21(1):e14321.
Score: 0.188
-
Shaw LM, Annesley TM, Kaplan B, Brayman KL. Analytic requirements for immunosuppressive drugs in clinical trials. Ther Drug Monit. 1995 Dec; 17(6):577-83.
Score: 0.101
-
Shaw LM, Bonner HS, Fields L, Lieberman R. The use of concentration measurements of parent drug and metabolites during clinical trials. Ther Drug Monit. 1993 Dec; 15(6):483-7.
Score: 0.088
-
Shaw LM, Kaplan B, Brayman KL. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem. 1998 Feb; 44(2):381-7.
Score: 0.029
-
Yatscoff RW, Shaw LM. Therapeutic monitoring of cyclosporine, FK-506, and rapamycin. Ther Drug Monit. 1992 Aug; 14(4):267-8.
Score: 0.020